BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of ...
Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that its Phase Ib/II study of ...
MNT speaks with three obesity medicine experts to find out more about the FDA-aproved Wegovy pill and how it's different from ...
A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual agonist, PG-102, ...
Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, ...
A new study shows many doctors do not offer self-injected birth control, even though it is safe and effective.
Vera Therapeutics stock rose on FDA acceptance of atacicept BLA for priority review in IgAN, a potential multi-billion dollar ...
Enable Injections, Inc. (“Enable”) a healthcare innovation company developing and manufacturing the enFuse® On-Body Delivery ...
The Brighterside of News on MSN
Antibody injections could replace slow IV drips in treating many diseases, MIT scientists find
Many patients endure hours-long infusions because antibody doses can exceed 100 milliliters, far beyond subcutaneous limits ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback